How ALPK1 Activation Orchestrates Antitumour Immunity: Mechanisms and Therapeutic Opportunities
Cancer Immuno Perspectives · 2025
DOI: 10.70996/cip.00007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immuno Perspectives, 2025.
Abstract (Originalsprache)
Immunotherapy has revolutionized cancer treatment, yet the efficacy of current strategies remains limited by tumour immune evasion and resistance.The alpha-kinase 1 (ALPK1) pathway, a pivotal cytosolic innate immune sensor for bacterial lipopolysaccharide precursors, has recently emerged as a novel and potent regulator of antitumour immunity .Unlike classical innate immune receptors such as Toll-like receptors (TLRs) and STING, ALPK1 recognizes ADP-heptose (ADP-Hep) and triggers a distinct signalling cascade primarily engaging NF-κB and MAPK pathways .This review delineates the molecular mechanisms by which ALPK1 activation orchestrates innate and adaptive immune responses within the tumour microenvironment (TME), including dendritic cell (DC) maturation, antigen cross-presentation, CD8+ T cell priming and infiltration, and modulation of immunosuppressive myeloid cells.Furthermore, we discuss the preclinical efficacy of ALPK1 agonists, their synergistic potential with immune checkpoint inhibitors (ICIs), and the unique advantages of this pathway over existing innate immune targets.Finally, we highlight ongoing clinical translation efforts, current challenges, and future perspectives for harnessing ALPK1 as a transformative target in cancer immunotherapy.
Zitieren
APA
(2025). How ALPK1 Activation Orchestrates Antitumour Immunity: Mechanisms and Therapeutic Opportunities. Cancer Immuno Perspectives. https://doi.org/10.70996/cip.00007
Vancouver
How ALPK1 Activation Orchestrates Antitumour Immunity: Mechanisms and Therapeutic Opportunities. Cancer Immuno Perspectives. 2025. doi:10.70996/cip.00007
BibTeX
@article{euvimed2025,
title = {How ALPK1 Activation Orchestrates Antitumour Immunity: Mechanisms and Therapeutic Opportunities},
journal = {Cancer Immuno Perspectives},
year = {2025},
doi = {10.70996/cip.00007}
}
EUVIMED